Cargando…
The Dohner fluorescence in situ hybridization prognostic classification of chronic lymphocytic leukaemia (CLL): the CLL Research Consortium experience
This study revisited the Dohner prognostic hierarchy in a cohort of 1585 well‐documented patients with chronic lymphocytic leukaemia. The duration of both time to first treatment (TTFT) and overall survival (OS) were significantly longer than observed previously, and this is at least partly due to i...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4963001/ https://www.ncbi.nlm.nih.gov/pubmed/26848054 http://dx.doi.org/10.1111/bjh.13933 |
_version_ | 1782444896357974016 |
---|---|
author | Van Dyke, Daniel L. Werner, Lillian Rassenti, Laura Z. Neuberg, Donna Ghia, Emanuella Heerema, Nyla A. Dal Cin, Paola Dell Aquila, Marie Sreekantaiah, Chandrika Greaves, Andrew W. Kipps, Thomas J. Kay, Neil E. |
author_facet | Van Dyke, Daniel L. Werner, Lillian Rassenti, Laura Z. Neuberg, Donna Ghia, Emanuella Heerema, Nyla A. Dal Cin, Paola Dell Aquila, Marie Sreekantaiah, Chandrika Greaves, Andrew W. Kipps, Thomas J. Kay, Neil E. |
author_sort | Van Dyke, Daniel L. |
collection | PubMed |
description | This study revisited the Dohner prognostic hierarchy in a cohort of 1585 well‐documented patients with chronic lymphocytic leukaemia. The duration of both time to first treatment (TTFT) and overall survival (OS) were significantly longer than observed previously, and this is at least partly due to improved therapeutic options. Deletion 13q remains the most favourable prognostic group with median TTFT and OS from fluorescence in situ hybridization (FISH) testing of 72 months and >12 years, respectively. Deletion 11q had the poorest median TTFT (22 months) and 17p deletion the poorest median OS (5 years). The percentages of abnormal nuclei were significantly associated with differential TTFT for the trisomy 12, 13q and 17p deletion cohorts but not for the 11q deletion cohort. From the date of the first FISH study, patients with >85% 13q deletion nuclei had a notably shorter TTFT (24 months). Patients with ≤20% 17p deletion nuclei had longer median TTFT and OS from the date of the first FISH study (44 months and 11 years), and were more likely to be IGHV mutated. |
format | Online Article Text |
id | pubmed-4963001 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-49630012016-07-27 The Dohner fluorescence in situ hybridization prognostic classification of chronic lymphocytic leukaemia (CLL): the CLL Research Consortium experience Van Dyke, Daniel L. Werner, Lillian Rassenti, Laura Z. Neuberg, Donna Ghia, Emanuella Heerema, Nyla A. Dal Cin, Paola Dell Aquila, Marie Sreekantaiah, Chandrika Greaves, Andrew W. Kipps, Thomas J. Kay, Neil E. Br J Haematol Haematological Malignancy This study revisited the Dohner prognostic hierarchy in a cohort of 1585 well‐documented patients with chronic lymphocytic leukaemia. The duration of both time to first treatment (TTFT) and overall survival (OS) were significantly longer than observed previously, and this is at least partly due to improved therapeutic options. Deletion 13q remains the most favourable prognostic group with median TTFT and OS from fluorescence in situ hybridization (FISH) testing of 72 months and >12 years, respectively. Deletion 11q had the poorest median TTFT (22 months) and 17p deletion the poorest median OS (5 years). The percentages of abnormal nuclei were significantly associated with differential TTFT for the trisomy 12, 13q and 17p deletion cohorts but not for the 11q deletion cohort. From the date of the first FISH study, patients with >85% 13q deletion nuclei had a notably shorter TTFT (24 months). Patients with ≤20% 17p deletion nuclei had longer median TTFT and OS from the date of the first FISH study (44 months and 11 years), and were more likely to be IGHV mutated. John Wiley and Sons Inc. 2016-02-05 2016-04 /pmc/articles/PMC4963001/ /pubmed/26848054 http://dx.doi.org/10.1111/bjh.13933 Text en © 2016 The Authors. British Journal of Haematology published by John Wiley & Sons Ltd. This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial‐NoDerivs (http://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
spellingShingle | Haematological Malignancy Van Dyke, Daniel L. Werner, Lillian Rassenti, Laura Z. Neuberg, Donna Ghia, Emanuella Heerema, Nyla A. Dal Cin, Paola Dell Aquila, Marie Sreekantaiah, Chandrika Greaves, Andrew W. Kipps, Thomas J. Kay, Neil E. The Dohner fluorescence in situ hybridization prognostic classification of chronic lymphocytic leukaemia (CLL): the CLL Research Consortium experience |
title | The Dohner fluorescence in situ hybridization prognostic classification of chronic lymphocytic leukaemia (CLL): the CLL Research Consortium experience |
title_full | The Dohner fluorescence in situ hybridization prognostic classification of chronic lymphocytic leukaemia (CLL): the CLL Research Consortium experience |
title_fullStr | The Dohner fluorescence in situ hybridization prognostic classification of chronic lymphocytic leukaemia (CLL): the CLL Research Consortium experience |
title_full_unstemmed | The Dohner fluorescence in situ hybridization prognostic classification of chronic lymphocytic leukaemia (CLL): the CLL Research Consortium experience |
title_short | The Dohner fluorescence in situ hybridization prognostic classification of chronic lymphocytic leukaemia (CLL): the CLL Research Consortium experience |
title_sort | dohner fluorescence in situ hybridization prognostic classification of chronic lymphocytic leukaemia (cll): the cll research consortium experience |
topic | Haematological Malignancy |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4963001/ https://www.ncbi.nlm.nih.gov/pubmed/26848054 http://dx.doi.org/10.1111/bjh.13933 |
work_keys_str_mv | AT vandykedaniell thedohnerfluorescenceinsituhybridizationprognosticclassificationofchroniclymphocyticleukaemiacllthecllresearchconsortiumexperience AT wernerlillian thedohnerfluorescenceinsituhybridizationprognosticclassificationofchroniclymphocyticleukaemiacllthecllresearchconsortiumexperience AT rassentilauraz thedohnerfluorescenceinsituhybridizationprognosticclassificationofchroniclymphocyticleukaemiacllthecllresearchconsortiumexperience AT neubergdonna thedohnerfluorescenceinsituhybridizationprognosticclassificationofchroniclymphocyticleukaemiacllthecllresearchconsortiumexperience AT ghiaemanuella thedohnerfluorescenceinsituhybridizationprognosticclassificationofchroniclymphocyticleukaemiacllthecllresearchconsortiumexperience AT heeremanylaa thedohnerfluorescenceinsituhybridizationprognosticclassificationofchroniclymphocyticleukaemiacllthecllresearchconsortiumexperience AT dalcinpaola thedohnerfluorescenceinsituhybridizationprognosticclassificationofchroniclymphocyticleukaemiacllthecllresearchconsortiumexperience AT dellaquilamarie thedohnerfluorescenceinsituhybridizationprognosticclassificationofchroniclymphocyticleukaemiacllthecllresearchconsortiumexperience AT sreekantaiahchandrika thedohnerfluorescenceinsituhybridizationprognosticclassificationofchroniclymphocyticleukaemiacllthecllresearchconsortiumexperience AT greavesandreww thedohnerfluorescenceinsituhybridizationprognosticclassificationofchroniclymphocyticleukaemiacllthecllresearchconsortiumexperience AT kippsthomasj thedohnerfluorescenceinsituhybridizationprognosticclassificationofchroniclymphocyticleukaemiacllthecllresearchconsortiumexperience AT kayneile thedohnerfluorescenceinsituhybridizationprognosticclassificationofchroniclymphocyticleukaemiacllthecllresearchconsortiumexperience AT vandykedaniell dohnerfluorescenceinsituhybridizationprognosticclassificationofchroniclymphocyticleukaemiacllthecllresearchconsortiumexperience AT wernerlillian dohnerfluorescenceinsituhybridizationprognosticclassificationofchroniclymphocyticleukaemiacllthecllresearchconsortiumexperience AT rassentilauraz dohnerfluorescenceinsituhybridizationprognosticclassificationofchroniclymphocyticleukaemiacllthecllresearchconsortiumexperience AT neubergdonna dohnerfluorescenceinsituhybridizationprognosticclassificationofchroniclymphocyticleukaemiacllthecllresearchconsortiumexperience AT ghiaemanuella dohnerfluorescenceinsituhybridizationprognosticclassificationofchroniclymphocyticleukaemiacllthecllresearchconsortiumexperience AT heeremanylaa dohnerfluorescenceinsituhybridizationprognosticclassificationofchroniclymphocyticleukaemiacllthecllresearchconsortiumexperience AT dalcinpaola dohnerfluorescenceinsituhybridizationprognosticclassificationofchroniclymphocyticleukaemiacllthecllresearchconsortiumexperience AT dellaquilamarie dohnerfluorescenceinsituhybridizationprognosticclassificationofchroniclymphocyticleukaemiacllthecllresearchconsortiumexperience AT sreekantaiahchandrika dohnerfluorescenceinsituhybridizationprognosticclassificationofchroniclymphocyticleukaemiacllthecllresearchconsortiumexperience AT greavesandreww dohnerfluorescenceinsituhybridizationprognosticclassificationofchroniclymphocyticleukaemiacllthecllresearchconsortiumexperience AT kippsthomasj dohnerfluorescenceinsituhybridizationprognosticclassificationofchroniclymphocyticleukaemiacllthecllresearchconsortiumexperience AT kayneile dohnerfluorescenceinsituhybridizationprognosticclassificationofchroniclymphocyticleukaemiacllthecllresearchconsortiumexperience |